A world without
Kineticos invests in innovative technologies and high performing teams to deliver solutions for antimicrobial resistance.
Kineticos aims to support companies developing differentiated and novel therapeutics, including novel antibiotics and anti-fungals, services, vaccines, and diagnostics. Kineticos is focused on investing in early stage companies with breakthrough technologies and a clear disease target with commercial potential. We help to strengthen teams and build businesses in partnership with others to make an impact on AMR.
AMR has been increasing globally over the past few decades leading to an increase in mortality and morbidity, surgical intervention, amputation, disfigurement, and prolonged hospital stays, affecting both developed and developing countries.
AMR represents a major challenge in the ability to treat infectious diseases. In the U.S., more than 2.80 million drug-resistant infections occurred and were responsible for 35,000 deaths in 2019. Globally, it is estimated that 4.95 million deaths were associated with bacterial AMR. This number includes 1.27 million deaths directly caused by resistant bacteria.
Despite the huge global burden, in the past 35 years, the FDA has approved only one new chemical entity (NCE). Kineticos is collaborating with leading investors and organizations aligned in supporting early-stage biotechs across all segments of AMR (diagnostics, services, therapeutics, and vaccines). Our focus is targeting indications with the highest unmet medical needs and top-priority pathogens defined by the WHO and CDC.
Kineticos provides more than capital. We leverage our operator and scientific expertise to help drive portfolio company strategy and growth. To address this unmet medical need, we will leverage our Foundry model to establish and build companies.
A major new proposal that followed was the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance or Pasteur Act, first introduced in 2020. The proposed legislation would create a “subscription model: in which the government would provide developers payments of $750 million to $3 billion each for antibiotics that target unmet needs.Congress should not wait around for the end of the antibiotic era, Washington Post | January, 2023
A lack of good tests makes identifying fungal disease more difficult. Some blood and urine tests for some yeasts and molds are accurate only half the time. Many molds need to be identified by specialists using microscopes. Misidentification is common, infectious-disease experts said.Deadly Fungal Infections Confound Doctors—'It's Going to Get Worse', Wall Street Journal | June, 2023
The number of drug-resistant C. auris cases tripled in 2021, from 476 in 2019 to 1,417 in 2021 with 17 states identifying their first case ever during the time frame. [We] need more: "a robust pipeline of new antimicrobial medicines," says BIO's AMR expert Emily Wheeler.Why We Need New Anitfungals – Fast, Good Day BIO | March, 2023
For a deeper understanding of the science behind AMR and to stay up to date with current trends, explore some of our highly recommended articles listed below.